- Home
- OFS vs MNOV Comparison
OFS vs MNOV Comparison
Compare OFS & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OFS | MNOV |
|---|---|---|
| Founded | 2001 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 65.0M | 72.7M |
| IPO Year | 2012 | 2005 |
Fundamental Metrics
Financial Performance| Metric | OFS | MNOV |
|---|---|---|
| Price | $5.09 | $1.60 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | ★ 95.5K | 91.9K |
| Earning Date | 03-02-2026 | 02-18-2026 |
| Dividend Yield | ★ 13.41% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.24 | N/A |
| Revenue | ★ $42,970,000.00 | $257,917.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $21.03 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.44 | $1.13 |
| 52 Week High | $9.80 | $2.06 |
Technical Indicators
Market Signals| Indicator | OFS | MNOV |
|---|---|---|
| Relative Strength Index (RSI) | 52.42 | 66.96 |
| Support Level | $4.80 | $1.43 |
| Resistance Level | $5.11 | $1.63 |
| Average True Range (ATR) | 0.16 | 0.07 |
| MACD | 0.05 | 0.03 |
| Stochastic Oscillator | 81.97 | 96.13 |
Price Performance
Historical ComparisonAbout OFS OFS Capital Corporation
OFS Capital Corp is an externally managed, closed-end, non-diversified management investment company. Its business objective is to generate current income and capital appreciation by investing in middle-market companies in the United States. The company focuses on investments in senior secured loans, including first lien, second lien, and unitranche loans, as well as subordinated loans and, to a lesser extent, warrants, and other equity securities.
About MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's strategies are to focus its developing activities on therapeutics for neurological disorders and fibrotic diseases.